logo
  

Evaxion Biotech Stock Gains 50% After Enrolling First Patient On Phase 2B Clinical Trial Of EVX-01

Shares of Evaxion Biotech A/S (EVAX) are gaining over 50% on Wednesday morning after the company enrolled its first patient in the global phase 2b clinical trial of EVX-01.

EVAX is currently trading at $3.0198, up $0.9798 or 48.0294%, on the Nasdaq. The stock has traded between $1.5100 and $25.0400 in the 52-week period.

Evaxion Biotech announced it had enrolled its first patient in the global phase 2b clinical trial of EVX-01, the company's personalized cancer therapy for the treatment of melanoma.

In the company's first phase 2b clinical trial, Evaxion is evaluating the efficacy and safety of EVX-01 in adults with metastatic melanoma. The trial is being conducted globally at clinical sites across the US, Europe, and Australia in collaboration with Merck & Co., Inc., which is supplying the trial with its PD-1 inhibitor, Keytruda.

Evaxion Biotech, a clinical-stage artificial intelligence-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Follow RTT